600062.SH
华润双鹤
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.83
+1.02%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
5.9x
Market Cap
CNY 16.44B
MomentumView details →
1D Return
+1.02%
YTD Return
−12.41%
RSI (14)
45.7
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
5.9x
Market Cap
CNY 16.44B
RSI (14)
45.7
MomentumView details →
1D Return
+1.02%
YTD Return
−12.41%
Similar companies
Latest newsMore news →
China Resources Double Crane announced that its lomustine capsules received a drug registration certificate and were approved for market launch by the National Medical Products Administration on August 25, 2026, with a 6-year data protection period.4d agoChina Resources Double-Crane Pharmaceutical's controlled subsidiary, China Resources Double-Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd., received drug registration certificate for its 0.15g oxcarbazepine tablets, approved by the National Medical Products Administration on August 25, 2026, deemed to have passed consistency evaluation.5d agoChina Resources Double Crane announced a major asset restructuring to acquire a 23.50% stake in Lier Chemical for cash, which would make it the controlling shareholder and change the actual controller to China Resources Co., Ltd.8d ago